BostonGene

Waltham, United States Founded: 2015 • Age: 11 yrs
Developer of cloud-based information and analytics platform to treat cancer
Annual revenue - Latest available
Total funding $200.0M 2 rounds
Employees - Tracked headcount
Investors 3 Known backers
Products 3 Services tracked
Competitors 9 Brand Intelligence

About BostonGene

BostonGene is a company based in Waltham (United States) founded in 2015. BostonGene has raised $200 million across 2 funding rounds from investors including NEC, Impact Investment Exchange and Japan Industrial Partners. BostonGene offers products and services including BostonGene Tumor Portrait™ Test, Liquid Biopsy, and Immunohistochemistry (IHC) Test. BostonGene operates in a competitive market with competitors including Helix, Syapse, Benchling, BioAge Labs and Ingenuity Systems, among others.

  • Headquarter Waltham, United States
  • Stage Unicorn
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Bostongene Corporation
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Health Technology & Digital Health Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $200 M (USD)

    in 2 rounds

  • Latest Funding Round
    $150 M (USD), Series B

    Apr 06, 2022

  • Investors
    NEC

    & 2 more

  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of BostonGene

BostonGene offers a comprehensive portfolio of products and services, including BostonGene Tumor Portrait™ Test, Liquid Biopsy, and Immunohistochemistry (IHC) Test.

Product name locked
Category locked
Primary

Offers comprehensive molecular profiling for cancer patients

Product name locked
Category locked
Locked

Provides non-invasive testing for tumor analysis

Product name locked
Category locked
Locked

Detects actionable biomarkers in cancer samples

People of BostonGene

Headcount 50-200
Employee Profiles 111
Employee Profiles
People
Maxim Sokolkov
Devops Engineer
People
David A.
VP Of Strategy
People
Zara Ohanyan
HR Business Partner
People
Joe Lennerz
Chief Scientific Officer

Unlock access to complete

Funding Insights of BostonGene

BostonGene has successfully raised a total of $200M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $150 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in BostonGene

BostonGene has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include NEC, Impact Investment Exchange and Japan Industrial Partners.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity investments are directed toward women empowerment initiatives.
Locked Locked Locked
Japan Industrial Partners is engaged in industrial revitalization and growth.
Locked Locked Locked
Cloud-based IT and networking solutions are provided globally.
Locked Locked Locked
Premium access

Investor details for BostonGene

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by BostonGene

Investments
Premium access

Investment portfolio details for BostonGene

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - BostonGene

Premium access

Detailed financials for BostonGene

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Bostongene Comparisons

BostonGene Primary company
Description
Developer of cloud-based information and analytics platform ...
Location
Waltham, United States
Founded Year
2015
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for BostonGene

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of BostonGene

BostonGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Helix, Syapse, Benchling, BioAge Labs and Ingenuity Systems, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Genomic database for clinical research is provided.
Locked Locked Locked
Developer of precision medicine for the treatment of cancer
Locked Locked Locked
Cloud-based bioinformatics platform is offered for biotech research.
Locked Locked Locked
Bioinformatics platform is provided for biomarkers and drug discovery.
Locked Locked Locked
Genomic data is analyzed and interpreted via web-based applications.
Locked Locked Locked
AI-based omics data analysis solutions are provided to researchers.
Premium access

Detailed competitors of BostonGene

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Bostongene

Premium access

Complete news archive for BostonGene

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about BostonGene

BostonGene was founded in 2015 and raised its 1st funding round 4 years after it was founded.

BostonGene is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.

BostonGene is a funded company, having raised a total of $200M across 2 funding rounds to date.

BostonGene was founded in 2015 and is headquartered in Waltham, United States. Operations focus on the healthcare and biotechnology sectors, where a cloud-based platform integrates AI, algorithms, and modern technologies. Molecular profiles of patient tumors are analyzed, combining tumor microenvironment, genetic data, and clinical information. Results are delivered directly to medical professionals through the MF Portrait platform to support oncology decisions.

BostonGene's top competitors include Helix, Syapse and Benchling.

BostonGene offers BostonGene Tumor Portrait™ Test, Liquid Biopsy, and Immunohistochemistry (IHC) Test.

BostonGene has 3 investors. Key investors include NEC, Impact Investment Exchange, and Japan Industrial Partners.

The valuation of BostonGene is $1B as of Apr 2022.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available